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Objectives The present study was performed to investigate the clinical implications of an implantable cardioverter-
defibrillator (ICD) in patients with vasospastic angina (VSA) resuscitated from lethal ventricular arrhythmia.
Background The prognosis of VSA is known to be good with medication; however, ventricular arrhythmia and cardiopulmo-
nary arrest are rare but life-threatening complications of this disease. The ICD is a proven modality for patients
with ventricular arrhythmia, but the clinical implications in this population remain to be elucidated.
Methods We conducted a retrospective, observational, multicenter study involving patients with an ICD due to docu-
mented ventricular arrhythmia and VSA diagnosed by acetylcholine provocation test. All patients were followed
up for appropriate ICD therapy, sudden cardiac arrest, or death from all causes.
Results Twenty-three patients were included in the present study and completely followed up. All patients are still alive.
During a follow-up of 2.9 years (median 2.1 years), 4 ventricular fibrillations and 1 episode of pulseless electrical
activity occurred in 5 patients (21.7%). There were no statistically significant differences in patient characteris-
tics between the recurrence and nonrecurrence groups, including medication, smoking status, and whether the
patient was or was not free of symptoms after ICD implantation.
Conclusions Patients with VSA and lethal ventricular arrhythmia are a population at high risk for recurrence of cardiopulmo-
nary arrest, and there is no reliable indicator for predicting recurrence of ventricular arrhythmia. Insertion of an
ICD with medication for VSA is appropriate for this high-risk population. (J Am Coll Cardiol 2012;60:908–13)
© 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.03.070m
o
iVasospastic angina (VSA) is 1 of the causes of chest pain
without coronary artery stenotic lesions. The prognosis of
VSA is generally good when treated with calcium-channel
blockers, with or without nitrates. However, VSA may
rarely trigger lethal ventricular arrhythmia and lead to
cardiopulmonary arrest (1–3). Moreover, increased ventric-
ular vulnerability and repolarization abnormalities have been
reported even during the symptom-free periods (4,5). The
implantable cardioverter-defibrillator (ICD) has become a
proven device for secondary prevention of sudden cardiac
death due to lethal ventricular arrhythmia (6,7). However,
the clinical implications of ICD as a secondary prevention of
malignant arrhythmia due to VSA are not well understood,
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performed a retrospective review of patients with lethal
ventricular arrhythmia due to VSA to assess the clinical
significance of ICD in this high-risk population.
Methods
Patient population. Patients with an ICD inserted for
lethal arrhythmia and VSA at Kameda Medical Center,
Yokohama Minami Kyosai Hospital, and Tokyo Metropolitan
Hiroo Hospital from December 1999 to September 2011 were
included retrospectively in this study. All patients fulfilled the
following criteria, defined by Myerburg et al. (2): 1) docu-
ented VF or sustained rapid ventricular tachycardia; 2) absence
f a previous history of angina pectoris or acute myocardial
nfarction; 3) normal left ventricular ejection fraction and no wallotion abnormality; 4) absence of significant coronary artery
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cause of lethal ventricular arrhythmia. A definite diagnosis was
made in all patients according to the Guidelines for Diagnosis
and Treatment of Patients with Vasospastic Angina of the
Japanese Circulation Society (8). All patients had angiographi-
cally normal coronary arteries, and all underwent acetylcholine
provocation test more than 1 week after the initial episode of
cardiac arrest. The acetylcholine provocation test was per-
formed according to the method included in the Guidelines for
Diagnosis and Treatment of Patients with Vasospastic Angina
of the Japanese Circulation Society (Fig. 1) (8). A medical
history was taken from all patients, followed by physical exami-
nation. Patients were considered smokers if they did not quit
smoking after ICD insertion. Approval was obtained from the
ethics committees of all participating hospitals (institutional review
boards of Kameda Medical Center, Yokohama Minami Kyosai
Hospital, and Tokyo Metropolitan Hiroo Hospital). Informed
consent from individual patients was not required under Japanese
law as the present study was purely observational.
Follow-up. All patients underwent insertion of an ICD
during their first admission after resuscitation, and were fol-
lowed up at each clinic after discharge. The medical history was
taken, adherence to prescribed medication was evaluated by
medical interview, and 12-lead electrocardiogram was per-
formed at each visit. Patients were also asked carefully at each
visit regarding the presence or absence of chest pain. The
length of follow-up was measured from the initial lethal
arrhythmic event.
Figure 1 Induction of Spasm in Both Left And Right Coronary A
(A) The left coronary artery was normal at baseline. (B) A spasm provocation test
anterior descending artery and left circumflex artery. The intracoronary injection of
that stenotic lesions of the left coronary artery had resolved spontaneously. (D) T
was provoked by intracoronary injection of acetylcholine. (C, F) After injection of isClinical follow-up data were ob-
tained by reviewing outpatient re-
cords. Study endpoints included
appropriate ICD therapy for ven-
tricular arrhythmia, sudden cardio-
pulmonary arrest due to pulseless
electrical activity (PEA), or asystole.
In the review of device use, ap-
propriate therapy was defined as an-
titachycardia or defibrillation treat-
ment administered for ventricular
tachyarrhythmia that had not terminated spontaneously before the
device administered the therapy. Appropriate treatment and di-
agnosis of arrhythmia were identified from episode electrograms
analyzed by expert staff.
Statistical analysis. All continuous variables are presented as
mean SD, and dichotomous data are shown as percentages.
Baseline characteristics were analyzed for significance of dif-
ferences between groups by 1-way analysis of variance for
continuous variables, and by the chi-square test or Fisher’s
exact test for categorical variables. Event-free survival curves were
constructed using the Kaplan-Meier survival method. In all
analyses, p  0.05 was taken to indicate statistical significance.
Results
Patient characteristics. Two of 25 patients with VSA and
lethal ventricular arrhythmia were excluded from the study
Abbreviations
and Acronyms
ICD  implantable
cardioverter-defibrillator
OHCA  out-of-hospital
cardiac arrest
PEA  pulseless electrical
activity
VSA  vasospastic angina
s by Intracoronary Injection of Acetylcholine
onducted with acetylcholine, and severe diffuse spasm was provoked in the left
choline was consecutively performed for the right coronary artery after confirming
t coronary artery was shown to be normal at baseline, but (E) severe vasospasm
ide dinitrate, all 3 vessels were released from spasm.rterie
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were included in the study. Demographic and clinical data
of the subjects are shown in Table 1. Echocardiography
showed no structural heart disease that contributed to
sudden cardiac death in any patient. All patients had normal
results on physical examination and no previous history of
cardiac disease. Four patients had atrial fibrillation on
electrocardiograms. No patients had abnormal findings on
echocardiography, or structural heart disease, or were taking
antiarrhythmic drugs. On acetylcholine provocation test, the
average number of coronary arteries with stenosis that were
provoked was 2.1  0.6. None of the patients had a family
history of coronary artery disease or sudden cardiac death.
Long-term follow-up. The follow-up period after the first
lethal arrhythmic event was 2.9 years (median 2.1 years). All
patients were still alive and symptom free with prescribed
medication after ICD implantation.
Kaplan-Meier survival concerning the arrhythmic event-
free survival curve is shown in Figure 2. During the
follow-up period, 5 patients reached endpoints, including 4
patients with appropriate therapy by ICD (Fig. 3) and 1
patient with PEA. Arrhythmias treated by ICD were all
ventricular fibrillation, which were identified by a review of
stored electrocardiograms, and there were no episodes of
ventricular tachycardia. All 4 patients with ventricular fi-
brillation were treated appropriately by ICD and resusci-
tated. One patient presented to hospital with sudden cardiac
arrest after chest pain, and electrocardiography at the
emergency department showed PEA. Intracardiac electro-
gram showed no ventricular arrhythmia. This patient was
successfully resuscitated, and is still alive. All patients who
reached the study endpoint were reevaluated with regard to
medication adherence by medical interview from patients
and family members. One patient with appropriate ICD
therapy discontinued prescribed medication on his own
Patient Characteristics at BaselineTable 1 Patient Characteristics at Baseline
Age, yrs 57.9 11.7
Male 22 (95.7)
Smoking 4 (17.4)
Chest pain before first arrhythmic event 4 (17.4)
Left ventricular ejection fraction, % 65.4 8.7
Atrial fibrillation 4 (17.1)
Acetylcholine provocation test
No. of coronary arteries with stenosis provoked by Ach test 2.2 0.5
LAD 15 (65.2)
LCX 17 (73.9)
RCA 19 (82.6)
Treatment
Diltiazem hydrochloride 23 (100)
Isosorbide mononitrate 14 (60.7)
Nicorandil 12 (52.2)
Hydroxymethylglutaryl-CoA reductase inhibitor 19 (82.6)
Arrhythmic events, PEA, or asystole 5 (21.7)
Values are mean  SD or n (%).
Ach  acetylcholine; LAD  left anterior descending coronary artery; LCX  left circumflex
coronary artery; PEA  pulseless electrical activity; RCA  right coronary artery.initiative, but adherence to medication was good in all other
patients. The average time for appropriate ICD therapy
from ICD insertion was about 1 year (range 50 to 600 days;
median 292 days). Only 2 of 5 patients with recurrent lethal
arrhythmia had symptoms of chest pain before ICD ther-
apy. However, the chest pain before ICD therapy was the
first episode for all of these patients.
After the first episode of appropriate ICD therapy, no
recurrent ICD therapy was administered in those 4 patients.
To determine the factors that influence the recurrence of
lethal arrhythmia in this population, the cohort was divided
according to whether appropriate ICD therapy was or was
not administered after discharge. However, there were no
factors that were significantly different between the 2 groups
(Table 2).
Discussion
Our retrospective observational study demonstrated a high
recurrence rate of ventricular arrhythmia in VSA patients,
and revealed the clinical implications of ICD in this
high-risk population. Moreover, predicting the risk of
recurrent arrhythmia was difficult, which also indicated that
ICD therapy would be appropriate for all patients resusci-
tated from ventricular arrhythmia and VSA, even if the
symptoms are well controlled by medication.
VSA and lethal arrhythmia. The prevalence of VSA in
patients who were resuscitated from cardiopulmonary arrest
and without significant coronary artery stenosis was re-
ported as 6% in Japan (1). Thus, VSA is not a rare cause of
out-of-hospital cardiac arrest (OHCA), and provocation
test was necessary to accurately diagnose the cause of
OHCA in patients without significant coronary artery
Figure 2 Kaplan-Meier Survival Curve
of VSA Patients With ICD Insertion
Kaplan-Meier survival curve is free from arrhythmic events among patients
with vasospastic angina (VSA) who underwent insertion of an implantable
cardioverter-defibrillator (ICD) for secondary prevention.stenosis. The occurrence of ventricular arrhythmia in pa-
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in 1 patient with documented ventricular tachycardia during
chest pain. Since then, many case reports have described the
relationship between VSA and ventricular lethal arrhyth-
mia, namely, sudden cardiac death. Although defining the
risk factors for stratifying the risk of sudden cardiac death in
Figure 3 Stored Intracardiac ICD Electrogram Obtained During
Ventricular fibrillation was terminated successfully by implantable cardioverter-defi
Characteristics of Patients With and Patients WTable 2 Characteristics of Patients With an
Variables
Age, yrs
Male
Smoking
Chest pain before first arrhythmic event
Left ventricular ejection fraction, %
Atrial fibrillation
Acetylcholine provocation test
No. of coronary arteries with stenosis provoked by Ach te
LAD
LCX
RCA
Treatment
Diltiazem hydrochloride
Isosorbide mononitrate
Nicorandil
Hydroxymethylglutaryl-CoA reductase inhibitorValues are mean  SD or n (%).
Abbreviations as in Table 1.VSA patients is important, this is still controversial. One
study indicated that obstructive coronary artery disease was
more common in patients with arrhythmia as compared to
patients without arrhythmia (10). However, there were no
correlations between lethal arrhythmia and the presence of
obstructive coronary artery disease in 3 other studies (1,11,12).
rrhythmic Episode
r (ICD) shock (arrow).
t Recurrence of Arrhythmiaients Without Recurrence of Arrhythmia
No Recurrence
(n  18)
Recurrence
(n  5) p Value
60.1 9.6 50.2 16.1 0.93
18 (100) 4 (80) 0.22
3 (16.7) 1 (20) 0.99
4 (22.2) 0 (0) 0.54
65.1 8.3 66.2 11.0 0.82
4 (22.2) 0 (0) 0.54
2.2 0.5 2.4 0.5 0.43
11 (61.1) 4 (80.0) 0.62
12 (66.7) 5 (100) 0.27
16 (88.9) 3 (60.0) 0.19
18 (100) 5 (100) —
12 (66.7) 2 (40.0) 0.34
10 (55.6) 2 (40.0) 0.64
16 (88.9) 3 (60.0) 0.20an A
brillatoithoud Pat
st
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obstructive coronary artery disease. Thus, patients with
OHCA require provocation test of VSA even if they do not
have obstructive coronary artery disease, because undiag-
nosed VSA without appropriate medication may pose a high
risk of sudden cardiac death. Indeed, in 1 of the studies cited
(1), a patient who died after resuscitation stopped taking his
medication on his own initiative. Moreover, this large
prospective cohort study showed that the incidences of
cardiac death and nonfatal myocardial infarction were sig-
nificantly increased in patients in whom medications were
reduced or discontinued. In the present study, 1 patient
treated with appropriate ICD shock also discontinued the
calcium-channel blocker. These observations suggest that
discontinuing or reducing medication may increase the risk
of recurrence of lethal arrhythmic events. Therefore, pa-
tients with VSA should not discontinue medical therapy,
particularly those with lethal arrhythmia.
We performed acetylcholine provocation test in all pa-
tients to diagnose VSA. According to the Japanese guide-
lines of VSA, both acetylcholine and ergonovine are rec-
ommended for provocation test. However, the biological
half-life of acetylcholine is extremely short compared with
that of ergonovine, and this short-acting effect of acetylcho-
line is important to perform vasospasm provocation test
safely in patients who are predicted to have severe symptoms
and multivessel coronary spasm (13). As the accuracy of
acetylcholine provocation test was reported to be good in
patients with multivessel vasospastic angina and some fatal
cases have been reported as complications of ergonovine
provocation test, acetylcholine is recommended for use in
this high-risk population (14,15).
ICD insertion for VSA. The present study included 23
patients with cardiopulmonary arrest caused by VSA in 3
hospitals in Japan. This study was large, second in size only
to another Japanese study that included 35 patients with
OHCA (1). However, all patients with VSA with lethal
arrhythmia underwent ICD insertion, and ours is the largest
number of such cases reported to date.
Takagi et al. (1) reported that the prognosis of patients
with VSA and OHCA was poorer than that of patients with
VSA but not OHCA. Importantly, an ICD was inserted in
14 patients and 2 appropriate shocks were applied; sudden
cardiac death occurred in 1 of the 21 patients without ICD
implantation, and this patient discontinued medication
himself before the event. Although maintenance of medi-
cation with calcium-channel blocker is very important to
prevent lethal arrhythmic events, particularly in patients
with OHCA and VSA as described, this sudden cardiac
death may have been prevented if this patient had had an
ICD.
Implantation of ICD in patients with VSA remains
controversial. According to the guidelines (16), patients
who survive cardiac arrest due to ventricular fibrillation or
hemodynamically unstable sustained ventricular tachycardia
are recommended for an ICD after exclusion of any “com-pletely reversible causes.” In VSA patients without lethal
arrhythmia (i.e., with only chest pain), the symptom is well
controlled with only medication, and the prognosis is good.
With regard to ICD, Meisel et al. (17) reported that, of 8
patients with VSA and lethal arrhythmia, ventricular ar-
rhythmia reoccurred in all 7 patients who had residual
symptoms despite using calcium-channel blocker, and they
concluded that patients who remain symptomatic despite
medical therapy should be considered for ICD insertion.
However, some studies have shown that vasospasm was
provoked even in patients whose symptoms were relieved by
calcium-channel blocker and/or vasodilator treatment
(18,19). Moreover, many cases of VSA and lethal arrhyth-
mia have been reported with ST-segment elevation and
without chest pain (2,4,20), indicating that symptoms are
unreliable during treatment with medication. In the present
study, all 4 patients treated with appropriate ICD shocks
reported feeling no chest pain and no discomfort before the
occurrence of lethal ventricular arrhythmia. As patients who
have VSA and ventricular arrhythmia represent a population
with a very high risk of sudden cardiac death, these results
suggest that the indication for ICD should not be decided
on the basis of symptoms, and all patients should be
considered for ICD insertion at the time of the first
ventricular arrhythmic event.
Limitation of ICD for ventricular arrhythmia in patients
with VSA. Although ICD therapy could be beneficial to
VSA patients with arrhythmia, there seems to be some
limitations. In the report of Letsas et al. (21), 1 patient also
with multivessel VSA had polymorphic ventricular fibrilla-
tion and PEA despite repeated defibrillation delivered by
the ICD. In the present study, 1 patient had sudden PEA
under optimal medication, and he also had multivessel
spasm provoked by acetylcholine. These observations sug-
gest that, in addition to ICD insertion, a novel therapeutic
modality that can ameliorate vascular function itself may be
needed, particularly in patients with multivessel VSA.
Study limitations. First, this study was not a randomized
controlled trial and was based on a small number of Japanese
patients in only 3 cardiovascular centers in Japan. Therefore,
the clinical significance of this study in patients of other
ethnic groups may need further evaluation. The cohort in
the present study included only patients with VSA who had
a history of lethal ventricular arrhythmia, and thus the data
shown here cannot be extrapolated to the whole VSA
population.
Medication compliance was evaluated only by medical
interview with patients, and that may have caused over-
estimation of patient compliance for prescribed medication.
We included only 23 of the 25 patients as 2 patients were
excluded for refusing ICD implantation, and that may have
resulted in selection bias. However, the incidence of recur-
rence of lethal ventricular arrhythmia remains high even if
these 2 patients were considered to be free of recurrence of
lethal ventricular arrhythmia.
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Although medical therapy is absolutely imperative for pa-
tients with VSA and a history of lethal arrhythmia, our
multicenter observational study of VSA patients who un-
derwent ICD insertion suggested that ICD therapy should
be strongly recommended for patients with VSA and lethal
arrhythmia. However, further large-scale studies are re-
quired to determine whether ICD therapy can improve the
prognosis of this high-risk group of patients.
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